The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO expects data from NOVA in the fourth quarter
CF-301 is being developed to be used in combination with standard of care antibiotics for the treatment of Staph bloodstream infections, including infective endocarditis, caused by drug-sensitive and
The patent was issued by the United States Patent and Trademark Office (USPTO) and will be listed in the US Food and Drug Administration’s Approved Drug Products with
Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol
The fifth patient is the third and final patient to be dosed in Cohort 2. The three patients in Cohort 2 received a dose of TT-034 of 1.25
"We are pleased by the FDA’s acceptance of our BLA for Zinbryta, which we believe has the potential to help people living with MS," said Gilmore O’Neill, vice
Navidea previously announced its intention to decrease its R&D expenses by divesting its non-core neuroimaging assets. This agreement follows through on the Company’s commitment to decrease cash burn
The acceptance of the NDA indicates the application is sufficiently complete to permit a substantive review by the FDA. "The FDA’s acceptance of our NDA filing brings us
"We are pleased that Triolimus has been designated an orphan drug for the treatment of angiosarcoma," commented Dr. Kevin Kozak, co-founder and Chief Medical Officer of Co-D Therapeutics.
Argatroban Injection is used to prevent or treat blood clots in adult patients who have developed antibodies to heparin or heparin-like products causing a decrease in platelets (known
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.